We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Tilray Brands, Inc. (TLRY) Dipped More Than Broader Market Today
Read MoreHide Full Article
In the latest trading session, Tilray Brands, Inc. (TLRY - Free Report) closed at $4.30, marking a -4.44% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.58% for the day. Elsewhere, the Dow saw a downswing of 1.18%, while the tech-heavy Nasdaq depreciated by 0.32%.
Coming into today, shares of the company had gained 1.81% in the past month. In that same time, the Medical sector gained 2.73%, while the S&P 500 lost 0.36%.
The upcoming earnings release of Tilray Brands, Inc. will be of great interest to investors. Simultaneously, our latest consensus estimate expects the revenue to be $268.23 million, showing a 28.03% escalation compared to the year-ago quarter.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.42 per share and revenue of $1.1 billion. These results would represent year-over-year changes of +61.47% and +20.56%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Tilray Brands, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.48% lower within the past month. Tilray Brands, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Why Tilray Brands, Inc. (TLRY) Dipped More Than Broader Market Today
In the latest trading session, Tilray Brands, Inc. (TLRY - Free Report) closed at $4.30, marking a -4.44% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.58% for the day. Elsewhere, the Dow saw a downswing of 1.18%, while the tech-heavy Nasdaq depreciated by 0.32%.
Coming into today, shares of the company had gained 1.81% in the past month. In that same time, the Medical sector gained 2.73%, while the S&P 500 lost 0.36%.
The upcoming earnings release of Tilray Brands, Inc. will be of great interest to investors. Simultaneously, our latest consensus estimate expects the revenue to be $268.23 million, showing a 28.03% escalation compared to the year-ago quarter.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.42 per share and revenue of $1.1 billion. These results would represent year-over-year changes of +61.47% and +20.56%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Tilray Brands, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.48% lower within the past month. Tilray Brands, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.